This is the authors' abstract. We don't add key points for this paper.
This study investigated the encapsulation of carvacrol, a natural phenolic compound with antimicrobial properties, into three different carriers: PHBV nanoparticles, β-cyclodextrin, and halloysite nanotubes. The encapsulated carvacrol was then integrated as a coating on PHBV film, and the release of the molecule in the headspace and food simulants was compared to the carvacrol release from the impregnated PHBV film. The results showed a high encapsulation efficiency (66 ± 5 %) but a slow release in the headspace (around 45 % in 30 days) for β-cyclodextrin, a moderate encapsulation efficiency (31 ± 2 %) but a faster release (more than 90 % in 10 days) for PHBV nanoparticles, and a very low encapsulation efficiency (less than 2 %) for halloysite. For all cases, the production of the film generated a 30 % loss of carvacrol, but the remaining concentration was homogeneous in all active films. The carvacrol release from the film in the headspace and food simulant demonstrated a faster release for coated films than impregnated ones, a higher affinity of carvacrol for ethanol than water (food simulant D1 with 50 % ethanol than A with 10 % ethanol), and a higher affinity for β-cyclodextrin than PHBV nanoparticles (coefficient partition higher for PHBV nanoparticles). These results highlighted that coated film with encapsulated carvacrol (PHBV nanoparticles and β-cyclodextrin) could be used for short shelf-life products (one week), while impregnated carvacrol film could be used for longer shelf-life products (a few months), the minimal inhibitory concentration against microorganisms being reached in headspace after this period for all cases.
No takes yet. Share an insight, caveat, or question.
Rzayeva et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: